RNAC Cartesian Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1453687 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-6.0%
TTM net income YoY-165.7%
TTM EPS YoY-259.4%
Revenue 3-yr CAGR-69.0%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-15,540.9%
Net margin-12,435.2%
FCF margin-8,770.0%
EBITDA margin-15,267.7%
Returns
ROE—
ROA-38.2%
ROIC (approx.)—
Asset turnover0.00x
Leverage & solvency
Liabilities / assets144.3%
Debt / equity—
Current ratio8.38x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.70x
Accruals ratio-11.6%
Payout ratio—
Capex / revenue120.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $2.80M | $38.91M |
| R&D expense | $58.03M | $45.10M |
| SG&A expense | $31.47M | $30.13M |
| Operating income | -$143.41M | -$43.90M |
| Interest expense | — | $0 |
| Pretax income | -$139.50M | -$77.14M |
| Income tax | -$9.19M | $287,000 |
| Net income | -$130.30M | -$77.42M |
| EBITDA | -$141.00M | -$42.70M |
| EPS (basic) | -5.02 | -4.48 |
| EPS (diluted) | -5.02 | -4.49 |
| Weighted avg. shares (diluted) | 25.97M | 17.36M |
| Balance sheet | ||
| Cash & equivalents | $125.14M | $214.28M |
| Receivables | $1.11M | $872,000 |
| Current assets | $129.28M | $216.63M |
| PP&E, net | $12.19M | $9.91M |
| Goodwill | $48.16M | $48.16M |
| Total assets | $296.41M | $435.02M |
| Current liabilities | $14.94M | $22.98M |
| Long-term debt | $0 | — |
| Total debt | $0 | — |
| Total liabilities | $422.65M | $441.82M |
| Shareholders' equity | -$126.24M | -$6.80M |
| Net debt | -$125.14M | — |
| Shares outstanding | 26.01M | 25.77M |
| Cash flow statement | ||
| Operating cash flow | -$73.94M | -$23.67M |
| Capital expenditure | $5.45M | $9.09M |
| Free cash flow | -$79.39M | -$32.77M |
| Investing cash flow | -$5.45M | -$8.74M |
| Financing cash flow | -$8.05M | $168.43M |
| Depreciation & amortization | $2.40M | $1.20M |
| Stock-based compensation | $10.52M | $6.58M |
Free plan shows the latest 2 periods; Pro shows all 12 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.